698-P: Interoperability as an Important Factor for Achieving the Full Potential of a Digital Diabetes Logbook

Abstract

A randomized controlled trial (RCT) has demonstrated the efficacy of a digital diabetes logbook (mySugr) in reducing diabetes distress compared to a control group without such an app. In a sub-group analysis, we analyzed whether those who have paired their glucose meter (glucose values were directly imported into the app) benefit differently than those who manually entered their glucose values. A total of 282 people were randomized to the intervention group using the app for 3 months (2:1 randomization; age: 51.2±14.6 years; 13.1% type 1, 66.7% type 2, 20.2% gestational diabetes). The per protocol population within the intervention group consisted of 232 participants who completed the 3-month follow-up and have used the app on ≥10% of the study days. Analysis of covariance was conducted with diabetes distress at the 3-month follow-up at dependent variable and connected glucose meter (yes/no) as independent variable, controlled for diabetes distress at baseline. Diabetes distress was measured with the Problem Areas in Diabetes (PAID) questionnaire. Within the per protocol population, 134 participants of the intervention group (57.8%) have used a connected glucose meter. Participants with a connected meter had significantly less diabetes distress at follow-up compared to participants who manually entered their glucose values (16.9±1.05 vs. 20.5±1.2, p = 0.027). There was no significant difference in demographic characteristics between the two groups. Participants with a connected meter had significantly more meal logs (3.3±2.2 vs. 2.0±1.2, p = 0.01) on days they have used the app. Overall, the digital diabetes logbook was able to reduce diabetes distress over a 3-month period. This reduction in diabetes distress was more pronounced in participants who used an interoperable glucose meter that automatically transferred glucose data into the app. Interestingly, there seems to be an increased interaction with the app regarding logging of meals in participants with a connected meter. Disclosure B.Kulzer: Advisory Panel; Berlin-Chemie AG, Abbott Diabetes, Bayer Inc., Dexcom, Inc., Novo Nordisk, Insulet Corporation, embecta, Research Support; Sanofi, Roche Diabetes Care. D.Ehrmann: Advisory Panel; Roche Diabetes Care, mySugr, Dexcom, Inc., Speaker's Bureau; Berlin-Chemie AG, Dexcom, Inc. N.Hermanns: Advisory Panel; Insulet Corporation, Research Support; Sanofi-Aventis Deutschland GmbH, Roche Diagnostics, Becton, Dickinson and Company, Speaker's Bureau; Dexcom, Inc., Berlin-Chemie AG. I.Vesper: None. V.L.Schaefer: Employee; Roche Diabetes Care. S.Silbermann: Employee; Roche Diabetes Care. J.Kober: Employee; mySugr. K.Finke-groene: None. T.Roos: None. E.Bingol: Employee; Roche Diabetes Care. Funding Roche Diabetes Care GmbH (DC000097)